TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04600505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive 2 inhalations of BGF MDI with propellant 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive 2 inhalations of BGF MDI with propellant 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive 2 inhalations of BGF MDI with propellant 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive 2 inhalations of BGF MDI with propellant 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive 2 inhalations of BGF MDI with propellant 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive 2 inhalations of BGF MDI with propellant 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive 2 inhalations of BGF MDI with propellant 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive 2 inhalations of BGF MDI with propellant 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive 2 inhalations of BGF MDI with propellant 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive 2 inhalations of BGF MDI with propellant 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive 2 inhalations of BGF MDI with propellant 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive 2 inhalations of BGF MDI with propellant 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive 2 inhalations of BGF MDI with HFA propellant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive 2 inhalations of BGF MDI with HFA propellant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive 2 inhalations of BGF MDI with HFA propellant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive 2 inhalations of BGF MDI with HFA propellant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive 2 inhalations of BGF MDI with HFA propellant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive 2 inhalations of BGF MDI with HFA propellant.
Study: NCT01926171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib plus WBRT
Description: Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.
Study: NCT03866785

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: interview
Description: The goal is to evaluate the needs, the constraints and representations of patients on the practice of physical activity.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Adult Physical Activity Questionnaire (APAQ)
Description: The goal of this questionnaire is to evaluate the sedentary lifestyle of patients.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Adult Physical Activity Questionnaire (APAQ)
Description: The goal of this questionnaire is to evaluate the sedentary lifestyle of patients.

Intervention type: DEVICE
Group type: OTHER
Intervention: Activity actigraph
Description: An activity actigraph will use by the patient for a week. It measures the level of physical activity and the sedentary lifestyle of patients.

Intervention type: DEVICE
Group type: OTHER
Intervention: Activity actigraph
Description: An activity actigraph will use by the patient for a week. It measures the level of physical activity and the sedentary lifestyle of patients.

Intervention type: OTHER
Group type: OTHER
Intervention: Peer training
Description: The goal of the peer training will organize once a week for 3 weeks for a patient.~After this training, they will have :~* Skills in physical activity advice~* Knowledge of functional signs (symptoms)~* Knowledge to examine heart rate and perceived effort rate

Intervention type: OTHER
Group type: OTHER
Intervention: Physical Activity Program
Description: During the Physical Activity Program, patients will be supervised by peers and a clubs and sports associations labeled sport-health by Olympic and Sports Committee of the Loire Department.~The peer will coach the patient once a week minimum for 3 months.
Study: NCT04073784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine combined with Aptinib and Toripalimab
Description: Gemcitabine injection, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles.~Apatinib for oral administration, 250mg, once a day. Apatinib maintenance.~Toripalimab injection, 240mg, Day 1 each 21day. Toripalimab maintenance.
Study: NCT02028117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enadenotucirev
Description: Oncolytic Virus
Study: NCT02053207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cog-Train Intervention
Description: Twenty-one days prior to surgery, patients will begin self-administering the intervention using an iPad tablet. This intervention will consist with daily sessions of at least 20 minutes of the Cog-Train task (the task and regimen used to obtain robust effects in previous studies by members of our group). Cog-Train is an n-back task - an adaptive working memory computer game that extends players' working memory capacity by getting progressively more difficult as the player's performance increases.
Study: NCT03082534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, Cetuximab
Description: Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection.~Cetuximab (Erbitux®) binds specifically to the epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of EGF and other ligands, such as transforming growth factor-alpha. Cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC), with in vitro assays and in vivo animal studies demonstrating that cetuximab inhibits the growth and survival of tumor cells expressing EGFR.
Study: NCT00025259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study: NCT03082534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, Cetuximab
Description: Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection.~Cetuximab (Erbitux®) binds specifically to the epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of EGF and other ligands, such as transforming growth factor-alpha. Cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC), with in vitro assays and in vivo animal studies demonstrating that cetuximab inhibits the growth and survival of tumor cells expressing EGFR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, Cetuximab
Description: Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection.~Cetuximab (Erbitux®) binds specifically to the epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of EGF and other ligands, such as transforming growth factor-alpha. Cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC), with in vitro assays and in vivo animal studies demonstrating that cetuximab inhibits the growth and survival of tumor cells expressing EGFR.
Study: NCT00364572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidural injection of etanercept
Description: 2 injections of etanercept 2 weeks apart with doses ranging from 2 mg to 6 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (control procedure)
Description: Two injections of epidural saline 2 weeks apart
Study: NCT04694521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: openSide to end colorectal anastomosis .
Description: open Side to end colorectal anastomosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open end end to end stapler anastomosis
Description: open end to end stapler anastomosis
Study: NCT01702090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114/ritonavir
Description: TMC114 800 mg (two tablets) once daily coadministered with ritonavir 100 mg (one capsule) once daily within 30 minutes after completion of a meal, and in combination with other ARVs.
Study: NCT01018472

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis
Description: 1 billion organisms twice daily either through a feeding tube or by mouth for 4 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A dilute preparation of pregestimil formula (similar in appearance to the probiotic product)
Study: NCT01945216

Intervention type: DRUG
Intervention: Alogliptin
Description: Alogliptin tablets
Study: NCT01118520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perindopril arginine
Description: 10mgs orally daily for the duration of the trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine 5mgs
Description: 5 mgs taken orally daily for the duration of the trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one daily
Study: NCT01185418

Intervention type: DRUG
Intervention: risperidone

Intervention type: DRUG
Intervention: aripiprazole

Intervention type: DRUG
Intervention: haloperidol

Intervention type: DRUG
Intervention: amisulpride

Intervention type: DRUG
Intervention: lactose
Study: NCT00869804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic/ Resistance Exercise Intervention
Description: The intervention will consist of a tailored home-based program of both aerobic (walking, using pedometer) and strength training exercises for upper and lower extremities using resistance power bands.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention control
Study: NCT01828619

Intervention type: PROCEDURE
Intervention: modified BuFlu conditioning
Description: The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m\^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.
Study: NCT02439450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viagenpumatucel-L
Description: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viagenpumatucel-L
Description: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viagenpumatucel-L
Description: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viagenpumatucel-L
Description: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg IV q2weeks for 18 weeks or until disease progression or unacceptable toxicity. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg IV q2weeks for 18 weeks or until disease progression or unacceptable toxicity. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: The recommended dose of KEYTRUDA (pembrolizumab) is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: The recommended dose of KEYTRUDA (pembrolizumab) is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: The recommended dose of ALIMTA (pemetrexed) when administered with carboplatin and pembrolizumab for the initial treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m2 administered as an intravenous infusion over 10 minutes prior to carboplatin on Day 1 of each 21-day cycle for 4 cycles. Pembrolizumab should be administered prior to ALIMTA when given on the same day.
Study: NCT03921619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoulder Sling
Description: soft shoulder sling that is placed around the forearm, with a strap draped over the shoulder
Study: NCT01391572

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: enlarge irradiation volume
Description: In Arm A, postsurgical radiation target volume includes tumor bed and elective nodes area

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Small volume radiation
Description: In Arm B, postsurgical radiation target volume includes tumor bed only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Study: NCT02280902

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Systematic follow-up (M3, M6, M12, M18, M24, M30) will be implemented to complete epidemiologic, clinical, therapeutic and biological data during a 30 months period. Specific measure of immune cells, markers of immune activation, immunoglobulins as described above will be performed at M3, M6, M12 and M24. A biologic collection (serum and cells) will be performed at the same time points for future prognostic studies.
Study: NCT00926731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1152
Description: Variable dose via a 7-day continuous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDAC (low dose cytosine arabinoside)
Description: 20 mg subcutaneous injection given twice daily
Study: NCT00395135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg BID
Description: Lorcaserin 10 mg tablet each morning and evening for a duration of 52 or 104 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo BID
Description: Matching placebo tablet each morning and evening for a duration of 52 or 104 weeks.
Study: NCT04072601

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Lactose monohydrate 50 mg, potato starch 45 mg, Gelatine 1,2 mg, Magnesium stearate 0,5, Talc 4,5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg
Description: Tablet, can be adjusted to 2 tablets if tolerated
Study: NCT03895398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition and psychosocial intervention with community participatory
Description: community participation to ensure the intervention is given to the study subject (underfive children)
Study: NCT04234789

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cardiopulmonary exercise testing with dynamic hyperinflation maneuver
Description: test performed as recommended by ATS guidelines

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: spirometry
Description: test performed as recommended by ATS guidelines

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pletysmography
Description: test performed as recommended by ATS guidelines

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: forced oscillometry technique
Description: test performed as recommended by ATS guidelines
Study: NCT02911740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine LAM Ag test
Description: TB diagnostic assay
Study: NCT01865812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid
Description: All participants were treated with OCA (oral administration, 10 mg, once daily \[QD\]) for 8 weeks and continued their prestudy dose of ursodeoxycholic acid (UDCA). After completion of the 8-week Primary Treatment Phase of the study and the 4-week follow-up period, during which time participants did not take OCA, all eligible participants were offered the opportunity to enter an open-label, long-term safety extension phase, during which they could receive 10 mg OCA QD for up to 2 years.
Study: NCT01184833

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under the routine practice setting.
Study: NCT02692040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3215
Description: Gut hormone analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3215
Description: Gut hormone analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3215
Description: Gut hormone analogue
Study: NCT00025259

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study: NCT02743871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06817024
Description: Subjects will be given one dose of PF-06817024 intravenously
Study: NCT02692040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3215
Description: Gut hormone analogue
Study: NCT00025259

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study: NCT02743871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for PF-06817024
Description: Subjects will be given one dose of placebo for PF-06817024 intravenously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for PF-06817024
Description: Subjects will be given one dose of placebo for PF-06817024 intravenously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for PF-06817024
Description: Subjects will be given one dose of placebo for PF-06817024 intravenously
Study: NCT02692040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3215
Description: Gut hormone analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3215
Description: Gut hormone analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3215
Description: Gut hormone analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3215
Description: Gut hormone analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3215
Description: Gut hormone analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3215
Description: Gut hormone analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3215
Description: Gut hormone analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3215
Description: Gut hormone analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3215
Description: Gut hormone analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3215
Description: Gut hormone analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3215
Description: Gut hormone analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G3215
Description: Gut hormone analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study: NCT02743871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for PF-06817024
Description: Subjects will be given one dose of placebo for PF-06817024 intravenously
Study: NCT00025259

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-Field Radiation Therapy
Description: Undergo IFRT
Study: NCT00025259

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-Field Radiation Therapy
Description: Undergo IFRT
Study: NCT02743871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for PF-06817024
Description: Subjects will be given one dose of placebo for PF-06817024 intravenously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for PF-06817024
Description: Subjects will be given one dose of placebo for PF-06817024 intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06817024
Description: Subjects will be given one dose of PF-06817024 subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for PF-06817024
Description: Subjects will be given one dose of placebo for PF-06817024 subcutaneously